December 14, 2020 06:55 AM ESTUpdated 12:03 PM
Coronavirus

Covid-19 roundup: Trump walks back plans to pri­or­i­tize White House staff for vac­cine; As­traZeneca drops sub­group of chil­dren from vac­cine tri­al — re­port

Amber Tong

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

As Amer­i­cans wait to re­ceive the first dos­es of Pfiz­er and BioN­Tech’s re­cent­ly au­tho­rized Covid-19 vac­cine, Pres­i­dent Don­ald Trump is walk­ing back plans for White …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Roche teams with Flare Ther­a­peu­tics on tran­scrip­tion fac­tors

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times